Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SPTX
Strong SellSinkerSeaport Therapeutics, Inc. · Healthcare · United States · $1.3B · Avg Vol: $3M/d
10
StockRankGet insider-trade alerts
Q
32
V
28
M
23
P/E (TTM)
—
ROE
—
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders.
FINANCIAL SUMMARY (USD)
| Year | 2024 | 2025 | TTM |
|---|---|---|---|
| Revenue | 0 | 0 | — |
| EPS | -1.21 | -1.94 | -2.52 |
| Shares | 53.0M | 53.0M | 53.5M |
| Debt | 5.0M | 5.1M | 5.0M |
| Equity | -24.8M | -92.5M | — |
| Op CF | -29.6M | -77.9M | -88.7M |
| Inv CF | -0.1M | -184.2M | — |
| Fin CF | 339.3M | -0.9M | — |
Loading 1Y...
PRICE (1Y)+14.6%
SMA 50SMA 200
Close
$23.28
RSI (14)
47.6
SCORE BREAKDOWN
Quality
32
ROIC
-37.0%20.9
ROE
—N/A
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-31.4%12.7
Piotroski
12.4
Int. Cover
—N/A
D/E Ratio
0.01x83.9
Current Ratio
18.00x95.1
Value
28
P/E (TTM)
—N/A
EV/EBITDA
-7.4x25.0
P/FCF
—N/A
P/B
3.1x44.3
P/S
—N/A
Div Yield
—N/A
Momentum
23
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
-4.3%14.6
EPS Rev 12W
—N/A
EPS Improve
-2%21.6
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$1.3B
P/E (Forward)
-9.7x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SPTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SPTX | Seaport Therapeutics, Inc.(you) | $1.3B | 10 | Strong Sell |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.2B | 8 | Strong Sell |
| AKTS | Aktis Oncology, Inc. | $1.4B | 11 | Strong Sell |
| AVLN | Avalyn Pharma Inc. | $1.5B | 10 | Strong Sell |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.1B | 11 | Strong Sell |
| LTGO | Latigo Biotherapeutics, Inc. | $1.5B | 8 | Strong Sell |
| TYRA | Tyra Biosciences, Inc. | $1.5B | 8 | Strong Sell |
| MAZE | Maze Therapeutics, Inc. | $1.5B | 8 | Strong Sell |
| SANA | Sana Biotechnology, Inc. | $1.2B | 6 | Strong Sell |
| SVRA | Savara Inc. | $1.1B | 12 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%